Cirrhosis is a common and dangerous chronic disease, the main causes of cirrhosis are chronic viral hepatitis, fatty liver disease and autoimmune liver disease, etc. In China, hepatitis B cirrhosis is the most common. According to statistics, in the entire population of chronic hepatitis B virus infection, about 30% of people will develop cirrhosis if they do not undergo standardized antiviral treatment, and some patients with cirrhosis are more likely to further deteriorate and eventually form liver cancer. Professor Tong Guangdong pointed out that patients with cirrhosis should start antiviral treatment in a timely manner, while taking adjustments in diet and lifestyle patterns to obtain better treatment results and quality of life. Without standardized antiviral treatment: 30% of chronic hepatitis B patients will develop cirrhosis Tong Guangdong introduced that recurrent inflammation caused by chronic hepatitis B virus infection is most likely to cause cirrhosis. “Chronic hepatitis B is a gradual process of development. The course of the disease is hidden, often the symptoms are not obvious, like a volcano or earthquake at the bottom of the sea is not easily detected, so some patients do not experience the obvious process of chronic hepatitis B suddenly become a state of cirrhosis. When hepatitis B inflammation appears, it will produce damage to liver cells, the body in the process of repair, fibrous connective tissue replaces part of the liver tissue, forming ‘scars’ on the liver, if liver cells are waiting for a long time to occur inflammatory necrosis, it will stimulate excessive proliferation of fibrous tissue in the liver, one by one, the ‘ scars’ accumulate, the liver will become hardened by the contraction of scar fibers, and eventually become cirrhosis.” Further, cirrhosis has the potential to transform into liver cancer. Studies have shown that for patients who already have severe fibrosis or early cirrhosis, without antiviral treatment, 7.4 percent of patients will progress to liver cancer within three years, and 20-23 percent will develop decompensated cirrhosis, both of which can be life-threatening. Tong Guangdong pointed out that among the entire population with chronic hepatitis B virus infection, 30% will eventually develop cirrhosis if they are not treated with antiviral therapy. As a high prevalence area of hepatitis B, Guangdong needs to pay more attention to the prevention and treatment of hepatitis B cirrhosis. Patients with cirrhosis should start antiviral treatment in a timely manner with the mindset of “don’t hesitate, don’t give up”. Treatment of cirrhosis: antiviral treatment is the key Hepatitis B virus replication is the root cause of disease progression. Studies have found that the replication of hepatitis B virus is not only closely related to the progression of hepatitis B, but also directly related to the occurrence of cirrhosis and liver cancer. If antiviral therapy is actively started, not only can disease progression be delayed, but also 18.8% of early cirrhosis can be completely reversed. Therefore, antiviral treatment is essential for patients with cirrhosis. Tong Guangdong introduced that the current antiviral treatment cannot yet cure hepatitis B, mainly because the hepatitis B virus remains in the nucleus of liver cells for a long time in the form of cccDNA, which is very stubborn and difficult to be completely removed. The 2010 edition of the Chinese Guidelines for the Prevention and Treatment of Hepatitis B clearly stipulates the treatment of cirrhosis: e antigen-positive patients with hepatitis B virus ≥ 104 copies/mL and e antigen-negative patients with hepatitis B virus ≥ 103 copies/mL should start immediately. Anti-viral therapy, with treatment aimed at delaying or reducing the occurrence of liver failure and hepatocellular carcinoma. Second, there are no clear criteria for discontinuation of antiviral therapy for hepatitis B cirrhosis, and long-term or even lifelong treatment is recommended. As the liver cells of cirrhotic patients have been severely damaged, the structure of liver lobules is disordered and there is much proliferation of fibrous tissue, although antiviral therapy can improve the function of liver cells and reduce liver fibrosis to a certain extent, it is already difficult for the liver to completely return to normal. Once the liver disease relapses after stopping the drug, the liver will inevitably be hit hard again and the patient will face the threat of liver failure. In short, do a good job in a protracted battle and do not stop the medication at will. Thirdly, as cirrhosis B requires long-term treatment, there is a risk of drug resistance to long-term treatment. At the same time, patients with cirrhosis B have a long disease duration and a complicated medication history, and there may be preexisting drug-resistant viruses. In patients with primary treatment, it is difficult to avoid the occurrence of drug resistance even if the most potent antiviral drug monotherapy is chosen. Therefore, to prevent drug resistance, combination treatment regimens can be adopted to minimize the risk of subsequent drug resistance. For example, lamivudine combined with adefovir, which have different targets and have stronger inhibitory effects on hepatitis B virus. Fourth, the long-term antiviral treatment process for patients with cirrhosis, do not think that after treatment, the condition has improved, do not go to the hospital for examination, remember, every 6-12 months to review the liver function and virus quantification, ultrasound and alpha-fetoprotein, to prevent changes in the condition for early treatment. There are taboos in the diet of patients with cirrhosis: eat less and more meals to avoid indigestible foods Tong Guangdong pointed out that there are also many taboos in the diet of patients with cirrhosis. For example, most patients with cirrhosis have changes in gastrointestinal function, which can easily lead to malnutrition, it is recommended to eat less and more meals, and patients with end-stage cirrhosis should add meals before bedtime. We should also pay attention to the changes in recipes, pay attention to the color, taste, soft and delicious, easy to digest. At the same time, the diet must be light, avoiding high fat, high cholesterol and indigestible, stimulating food, and also have a comprehensive and rich vitamin: B vitamins have an important physiological role in promoting digestion, protecting the liver and preventing fatty liver; vitamin C can promote metabolism and has detoxification functions; fat-soluble vitamins A, D and E have different degrees of protective effects on the liver. In addition, patients with cirrhosis are forbidden to drink alcohol. Alcohol in the body is mainly metabolized through the liver and excreted. Drinking alcohol will increase the burden on the liver, which is already declining in function. Therefore, it should be absolutely forbidden to drink all drinks containing alcohol and to use less stimulating foods such as chili and mustard. In short, patients with cirrhosis should quit smoking and avoid alcohol, strengthen nutrition, exercise properly, get enough rest, live a regular life, be positive and build up confidence to overcome the disease. Life conditioning coupled with antiviral treatment, it is not a dream for patients with cirrhosis B to obtain long-term survival.